Serial Number 87497304
606

Registration Progress

Application Filed
Jun 20, 2017
Under Examination
Feb 27, 2018
Approved for Publication
Jan 2, 2018
Published for Opposition
Jan 2, 2018
Registered

Trademark Image

Basic Information

Serial Number
87497304
Filing Date
June 20, 2017
Published for Opposition
January 2, 2018
Abandonment Date
April 5, 2021
Drawing Code
2

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Apr 5, 2021
Classes
001 005 042

Rights Holder

CytomX Therapeutics, Inc.

03
Address
151 Oyster Point Blvd, Suite 400
South San Francisco, CA 94080

Ownership History

CytomX Therapeutics, Inc.

Original Applicant
03
South San Francisco, CA

CytomX Therapeutics, Inc.

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
Stephanie K. Wade

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

50 events
Date Code Type Description Documents
Apr 5, 2021 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Apr 5, 2021 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Aug 1, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 31, 2020 EX5G S SOU EXTENSION 5 GRANTED Loading...
Jul 29, 2020 EXT5 S SOU EXTENSION 5 FILED Loading...
Jul 29, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 7, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 5, 2020 EX4G S SOU EXTENSION 4 GRANTED Loading...
Feb 5, 2020 EXT4 S SOU EXTENSION 4 FILED Loading...
Feb 5, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 30, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 30, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jan 21, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jan 21, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Oct 16, 2019 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Oct 16, 2019 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Aug 22, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 19, 2019 EX3G S SOU EXTENSION 3 GRANTED Loading...
Aug 19, 2019 EXT3 S SOU EXTENSION 3 FILED Loading...
Aug 19, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 19, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 15, 2019 EX2G S SOU EXTENSION 2 GRANTED Loading...
Feb 15, 2019 EXT2 S SOU EXTENSION 2 FILED Loading...
Feb 15, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 18, 2018 NOAC E CORRECTED NOA E-MAILED Loading...
Sep 18, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 17, 2018 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 17, 2018 DPCC D DIVISIONAL PROCESSING COMPLETE Loading...
Sep 17, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Aug 21, 2018 DRRR I DIVISIONAL REQUEST RECEIVED Loading...
Aug 21, 2018 ERTD I TEAS REQUEST TO DIVIDE RECEIVED Loading...
Aug 20, 2018 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 20, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 27, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 20, 2018 CHPB I POST PUBLICATION AMENDMENT - ENTERED Loading...
Feb 16, 2018 APET A ASSIGNED TO PETITION STAFF Loading...
Feb 6, 2018 EPPA I TEAS POST PUBLICATION AMENDMENT RECEIVED Loading...
Jan 2, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 2, 2018 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 13, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 26, 2017 ALIE A ASSIGNED TO LIE Loading...
Nov 14, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 14, 2017 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Nov 14, 2017 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Nov 14, 2017 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Nov 14, 2017 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Nov 10, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Nov 10, 2017 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Nov 9, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 8, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...

Detailed Classifications

Class 001
Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use
Class 005
Infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens
Class 042
Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network

Additional Information

Design Mark
The mark consists of three semi-circles aligned next to each other. The first semi-circle has its vertical opening facing to the right. It is separated by a narrow white space from the second semi-circle, whose vertical opening faces to the left. The third semi-circle's vertical opening faces to the right. The tips of the circular apexes of the second and third semi circles are adjoined to each other.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
001 005 042